NLM Title Abbreviation
Exp Hematol Oncol
Experimental Hematology & Oncology
DOI of Published Version
Breast cancer is a common cause of brain metastases, with metastases occurring in at least 10-16 % of patients. Longer survival of patients with metastatic breast cancer and the use of better imaging techniques are associated with an increased incidence of brain metastases. Unfortunately, patients who develop brain metastases tend to have poor prognosis with short overall survival. In addition, brain metastases are a major cause of morbidity, associated with progressive neurologic deficits that result in a reduced quality of life. Tumor subtypes play a key role in prognosis and treatment selection. Current therapies include surgery, whole-brain radiation therapy, stereotactic radiosurgery, chemotherapy and targeted therapies. However, the timing and appropriate use of these therapies is controversial and careful patient selection by using available prognostic tools is extremely important. This review will focus on current treatment options, novel therapies, future approaches and ongoing clinical trials for patients with breast cancer brain metastases.
OAfund, Breast cancer, Brain metastasis, Metastatic breast cancer
Journal Article Version
Version of Record
Published Article/Book Citation
Leone and Leone Exp Hematol Oncol (2015) 4:33 DOI 10.1186/s40164-015-0028-8
© 2015 Leone and Leone
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.